Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7125070 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| SCHEMBL7129859 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| Pachastrissamine SCHEMBL766801 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| SCHEMBL6276277 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| 2-Epi Jaspine B SCHEMBL7125067 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| SCHEMBL7596269 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| 2-Epi Jaspine B SCHEMBL17356379 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| SCHEMBL17350826 | 0.85 | SPHK1 (0.73) | SPHK2SPHK1 | |
| SCHEMBL22576609 | 0.85 | SPHK1 (0.73) | SPHK2SPHK1 | |
| SCHEMBL11117820 | 0.81 | SPHK2 (0.69) | SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9301965-B2 | Method of treating ovarian cancer using a PKC inhibitor | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301965-B2 | Method of treating ovarian cancer using a PKC inhibitor | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150366883-A1 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150366883-A1 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366883-A1 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR | PRKD1, PRKCI, ACP3 | SPHK2 254/4885SPHK1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.